ConsensusCurrent

FDA — Adzynma September 2026 boxed-warning safety update

FDA, 2026

Neutralizing ADAMTS13 antibodies may cause loss of response and serious outcomes including death during recombinant ADAMTS13 treatment of cTTP. Assess activity/inhibitors before and periodically during treatment; manage changes with the specialist team.

Expert opinionLow certainty

View source guideline

Clinical Context & Relevant Topics (1)

Disease Reference

Thrombotic Thrombocytopenic Purpura (TTP)

Recognition of thrombotic microangiopathy, PLASMIC risk, ADAMTS13 testing, immediate plasma exchange, steroids, caplacizumab, and ICU complications.

View Topic Context →